



RECEIVED
JAN 06 2003
TECH CENTER 1600/2900

LARGE ENTITY TRANSMITTAL FORM
FOR REPLY AFTER FINAL UNDER 37 C.F.R. § 1.116

BOX AF

Assistant Commissioner for Patents
Washington, DC 20231

December 31, 2002

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☐ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:


	CLAIMS REMAINING AFTER AMENDMENT					HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	5	-	20	=	0		\$ 18	\$0.00	
INDEPENDENT	1	-	3	=	0		\$ 84	\$0.00	
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM							\$280	\$0.00	
							TOTAL	\$0.00	

- ☐ Petition for () month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ Check(s) in the amount of \$0.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977

MaryAnne Armstrong, PhD, #40,069

GMM/MAA/csm
1110-0280P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s)

(Rev. 09/30/02)



#11
Cond. P. Dec.
1/10/03

BOX AF
REPLY UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1648
PATENT
1110-0280P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Takehiro YATOMI Conf: 1332
Appl. No.: 09/701,486 Group: 1648
Filed: November 29, 2000 Examiner: Z. Lucas
For: PREVENTIVES/REMEDIES FOR AUTOIMMUNE
DEMYELINATING DISEASES

RECEIVED
JAN 06 2003
TECH CENTER 1600/2900

RESPONSE

Assistant Commissioner for Patents
Washington, DC 20231

December 31, 2002

Sir:

The following Amendments and Remarks are respectfully submitted in response to the Office Action issued October 1, 2002, in connection with the above-identified application.

IN THE CLAIMS:

Please cancel claim 3 without prejudice or disclaimer of the subject matter contained therein.

Please replace claim 1 with the following amended claim.

*10-20-02
Enter*

1. (Twice Amended) A method for treating autoimmune demyelinating diseases which comprises administering to a patient in need thereof an effective amount of a Fas antagonist, which is a substance that inhibits Fas-Fas ligand binding and suppresses apoptosis.